- Home
- AXTA vs JAZZ Comparison
AXTA vs JAZZ Comparison
Compare AXTA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXTA | JAZZ |
|---|---|---|
| Founded | 1910 | 2003 |
| Country | United States | Ireland |
| Employees | 12300 | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 10.4B |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AXTA | JAZZ |
|---|---|---|
| Price | $27.46 | $179.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $36.71 | ★ $215.92 |
| AVG Volume (30 Days) | ★ 2.6M | 974.4K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $5,117,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $3.56 | $6.17 |
| Revenue Next Year | $2.93 | $7.66 |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.28 | $95.49 |
| 52 Week High | $35.72 | $198.00 |
Technical Indicators
Market Signals| Indicator | AXTA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 18.41 | 50.46 |
| Support Level | $27.43 | $176.67 |
| Resistance Level | $31.01 | $182.99 |
| Average True Range (ATR) | 0.98 | 6.39 |
| MACD | -0.59 | -0.90 |
| Stochastic Oscillator | 0.54 | 28.45 |
Price Performance
Historical ComparisonAbout AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.